|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
Miravant (MRVT) To Initiate PHOTREX Confirmatory Phase III Clinical Trial In Europe; Global CRO Kendle Selected To Provide Clinical Development And Trial Management Services
10/19/2005 5:12:59 PM
SANTA BARBARA, Calif.--(BUSINESS WIRE)--March 10, 2005--Miravant Medical Technologies (OTCBB:MRVT), a pharmaceutical development company specializing in PhotoPoint(R) photodynamic therapy (PDT), today announced that it will conduct a confirmatory Phase III clinical trial for PHOTREX(TM) (rostaporfin, formerly known as SnET2) at investigational sites in Central and Eastern Europe (CEE) and the United Kingdom. Miravant has selected Kendle (Nasdaq:KNDL), a leading international contract research organization with locations worldwide, to provide clinical development services for the Phase III trial. The randomized, placebo-controlled study, reviewed by the U.S. Food and Drug Administration (FDA) under a Special Protocol Assessment, will evaluate a range of patients with wet age-related macular degeneration (AMD), including both classic and occult lesions.
"Miravant selected Kendle based on its significant Phase III experience and expertise in Europe, particularly its patient access capabilities in CEE," said Gary S. Kledzik, Ph.D., chairman and chief executive officer. "These countries are proving to be desirable locations for conducting pharmaceutical clinical trials, with motivated, cost-effective research centers and high patient productivity. We are confident that Kendle's integrated study teams can efficiently manage the trial and satisfy our strategic regulatory requirements."
|
|
|
|
|
|
|
|
|
|
|